IQVIA Holdings Inc. (NYSE:IQV) Receives $257.57 Consensus PT from Brokerages

IQVIA Holdings Inc. (NYSE:IQV) has been given a consensus rating of “Moderate Buy” by the fifteen research firms that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $257.57.

Several equities analysts have recently issued reports on IQV shares. Evercore ISI reduced their target price on IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a report on Friday, May 3rd. Guggenheim lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Barclays boosted their target price on shares of IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Robert W. Baird decreased their price target on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a research note on Friday, May 3rd. Finally, SVB Leerink initiated coverage on IQVIA in a research note on Monday, February 26th. They issued an “outperform” rating and a $290.00 price objective on the stock.

IQVIA Stock Up 0.5 %

IQVIA stock opened at $227.10 on Tuesday. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88. The stock has a market cap of $41.38 billion, a PE ratio of 31.02, a price-to-earnings-growth ratio of 2.09 and a beta of 1.52. IQVIA has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The firm’s 50-day simple moving average is $237.60 and its 200 day simple moving average is $228.31.

Insider Buying and Selling at IQVIA

In other news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares in the company, valued at approximately $1,313,642.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Institutional Trading of IQVIA

Institutional investors have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC lifted its stake in shares of IQVIA by 17.5% in the 4th quarter. Los Angeles Capital Management LLC now owns 118,616 shares of the medical research company’s stock valued at $27,445,000 after acquiring an additional 17,677 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in IQVIA by 4.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock worth $532,070,000 after purchasing an additional 93,194 shares during the period. International Assets Investment Management LLC purchased a new stake in shares of IQVIA during the fourth quarter valued at approximately $13,759,000. Schwartz Investment Counsel Inc. increased its stake in shares of IQVIA by 4.1% in the fourth quarter. Schwartz Investment Counsel Inc. now owns 178,690 shares of the medical research company’s stock worth $41,345,000 after buying an additional 7,050 shares during the period. Finally, Principal Securities Inc. bought a new stake in IQVIA during the 4th quarter valued at $4,976,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.